Sinya Ashizuka

Dr. Sinya Ashizuka

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
SASinya Ashizuka
Sinya Ashizuka
HIHaruhiko Inatsu
Haruhiko Inatsu
TKToshihiro Kita
Toshihiro Kita
KKKazuo Kitamura
Kazuo Kitamura
Background and Aims Adrenomedullin (AM) is a multifunctional biologically active peptide that has an ameliorative effect against inflammatory bowel disease in several experimental models. We reported the first case where AM infusion dramatically improved symptoms and colonoscopy findings in patients with refractory ulcerative colitis (UC). To confirm the reproducibility of the efficacy and safety of AM infusion, this pilot study evaluated the clinical feasibility of intravenous administration of AM in patients with refractory UC. Methods Seven patients with active refractory UC participated and received intravenous infusion of AM (1.5 pmol/kg/min) for 8 h daily for 14 days, and their Disease Activity Index (DAI) were evaluated before and 2 and 12 weeks after beginning AM administration. Results DAI were improved in all patients after AM administration. Within 2 weeks, marked declines in DAI (≥3 points and ≥30 %) were observed in six patients (85.7 %), while a more modest decline was observed in one patient (14.3 %). Overall mean DAI improved from 9.3 ± 0.6 at baseline to 4.6 ± 0.8 at 2 weeks, and then to 1.2 ± 0.5 at 12 weeks. Endoscopic examination revealed substantial amelioration of ulcers, with mucosal healing and scarring. Four patients remained in clinical remission 12 months after AM treatment. AM administration produced significant increases in plasma AM concentrations (approximately 2.5-fold) that had a mild effect on blood pressure and heart rate, but with no serious adverse effects. Conclusion AM is a potentially useful agent that acts via a novel mechanism to safely induce mucosal healing and clinical remission in patients with refractory UC.

23 August 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
SASinya Ashizuka
Sinya Ashizuka
TKToshihiro Kita
Toshihiro Kita
HIHaruhiko Inatsu
Haruhiko Inatsu
KKKazuo Kitamura
Kazuo Kitamura
Adrenomedullin (AM) is a bioactive peptide with various physiological functions, including vasodilation, angiogenesis, anti-inflammation, organ protection, and tissue repair. AM suppresses inflammatory cytokine production in the intestinal mucosa, improves vascular and lymphatic regeneration and function, mucosal epithelial repair, and immune function in the intestinal bacteria of animal models with intestinal inflammation. We have been promoting translational research to develop novel therapeutic agents for inflammatory bowel disease (IBD) using AM and have started clinical research for IBD patients since 2010. A multicenter clinical trial is currently underway in Japan for patients with refractory ulcerative colitis and Crohn’s disease. Moreover, since current AM administration is limited to continuous intravenous infusion, the development of a subcutaneous formulation using long-acting AM is underway for outpatient treatment.

1 February 2013 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
SASinya Ashizuka
Sinya Ashizuka
TKToshihiro Kita
Toshihiro Kita
HIHaruhiko Inatsu
Haruhiko Inatsu
KKKazuo Kitamura
Kazuo Kitamura

1 February 2006 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
SASinya Ashizuka
Sinya Ashizuka
RNRyosuke Nishiura
Ryosuke Nishiura
NINaoto Ishikawa
Naoto Ishikawa
JYJunichi Yamaga
Junichi Yamaga
HIHaruhiko Inatsu
Haruhiko Inatsu
TETanenao Eto
Tanenao Eto

31 October 2023 in Intestinal Research
Verified
Journal Article
Open access
PDF file
TNTakahiro Nagata
Takahiro Nagata
SFSadahiro Funakoshi
Sadahiro Funakoshi
YKYi-Ling Ko
Yi-Ling Ko
SSSatoshi Shakado
Satoshi Shakado
KYKenji Yokoyama
Kenji Yokoyama
FHFumihito Hirai
Fumihito Hirai
Background/Aims: The frequency and details of nonalcoholic fatty liver disease (NAFLD) complications in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to clarify characteristics of NAFLD in patients with IBD.Methods: We retrospectively identified and enrolled patients with IBD diagnosed with or without NAFLD by undergoing abdominal computed tomography (CT) at our institution between 2005 and 2020. The primary endpoint was the complication rate of NAFLD in patients with IBD. Secondary endpoints were the clinical characteristics of nonobese patients with IBD and comorbid NAFLD and their association with nutritional and inflammatory parameters.Results: Twenty-one (21.9%) of 96 eligible patients with IBD also had NAFLD. In nonobese patients (defined as patients with a body mass index <25 kg/m2), C-reactive protein (CRP; P<0.001) and alanine aminotransferase (P=0.018) levels were higher and the albumin level (P=0.005) and prognostic nutritional index (PNI; P=0.002) values were lower in patients with NAFLD than in those without NAFLD. The PNI value was positively correlated (P<0.001) and the CRP level was negatively correlated (P=0.001) with the hepatosplenic ratio. However, in the NAFLD combined group, PNI (P<0.05) and CRP values (P<0.001) were improved over time after CT imaging by continuing IBD treatment.Conclusions: Worsening nutritional and inflammatory status in IBD patients is associated with complications of NAFLD. Diagnosis of NAFLD in IBD patients using CT imaging might be useful not only for early detection of NAFLD but also in assessing the need for therapeutic intervention for IBD.

1 May 2012 in Gastroenterology
Verified
Journal Article
Closed access
SASinya Ashizuka
Sinya Ashizuka
HIHaruhiko Inatsu
Haruhiko Inatsu
TKToshihiro Kita
Toshihiro Kita
KKKazuo Kitamura
Kazuo Kitamura